Treatment of vascular dementia - Evidence from clinical trials with cholinesterase inhibitors

Timo Erkinjuntti, Gustavo Román, Serge Gauthier

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Cerebrovascular disease (CVD), as well as secondary ischemic brain injury from cardiovascular disease, are common causes of dementia and cognitive decline in the elderly. Also, CVD frequently contributes to cognitive loss in patients with Alzheimer's disease (AD). Progress in understanding the pathogenetic mechanism involved in vascular cognitive impairment and vascular dementia (VaD) has resulted in promising treatments of these conditions. Cholinergic deficits in VaD are due to ischemia of basal forebrain nuclei and of cholinergic pathways and can be treated with the use of the cholinesterase inhibitors used in AD. Controlled clinical trials with donepezil, galantamine, and rivastigmine in VaD, as well as in patients with AD plus CVD, have demostrated improvement in cognition, behavior and activites of daily living.

Original languageEnglish (US)
Pages (from-to)603-605
Number of pages3
JournalNeurological Research
Issue number5
StatePublished - Jul 2004


  • Cerebrovascular disease
  • Cholinesterase inhibitors
  • Dementia
  • Elderly
  • Vascular dementia

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Treatment of vascular dementia - Evidence from clinical trials with cholinesterase inhibitors'. Together they form a unique fingerprint.

Cite this